Bi-layer Acetaminophen Tramadol Tablet Synchronized Release

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Developing an extended release dosage form for a combination of acetaminophen and tramadol that achieves synchronized release of both drugs over an extended period is challenging due to differences in water solubility and absorption rates, leading to unpredictable plasma concentration fluctuations and frequent dosing requirements.

Innovation Solution

The use of a complexed tramadol material with an anionic polymer, specifically carrageenan, to create a pharmaceutical composition that exhibits coordinated sustained release, ensuring a synchronized release profile of acetaminophen and tramadol over 4 to 12 hours, achieved through a bi-layer tablet design with an immediate release layer and an extended release layer.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Speed

If immediate release dosage form is used for tramadol/APAP combination, then onset of action is fast, but dosing frequency must be frequent (every 4-6 hours)

Engineering Contradiction:
Improveonset of actionVSAvoidduration of action
Core Design Contradiction:
SpeedVSDuration of action of moving object

Solution Approach 1:

The invention divides the single dosage form into two distinct layers: an immediate release layer containing APAP for rapid onset of action, and an extended release layer containing tramadol for prolonged duration of action. This segmentation allows each layer to independently control the release profile of its respective drug, resolving the contradiction between fast onset and long duration.

Inventive Principle:
Principle #1Segmentation

2Duration of action of moving object

If extended release dosage form is used for tramadol, then duration of action is extended, but release profile becomes unpredictable due to solubility differences

Engineering Contradiction:
Improveduration of actionVSAvoidrelease profile predictability
Core Design Contradiction:
Duration of action of moving objectVSReliability

Solution Approach 1:

The invention applies different release characteristics to different parts of the dosage form: the immediate release layer provides rapid drug delivery for quick onset, while the extended release layer provides controlled, sustained delivery for prolonged effect. Each layer is specifically designed with appropriate excipients and structure to achieve its intended release profile, making the overall system predictable and reliable.

Inventive Principle:
Principle #3Local quality

3Ease of manufacture

If hydrophilic polymer matrix approach is used for extended release, then manufacturing is simplified, but coordinated release of APAP and tramadol is difficult to achieve

Engineering Contradiction:
Improvemanufacturing simplicityVSAvoidcoordinated release profile
Core Design Contradiction:
Ease of manufactureVSManufacturing precision

Solution Approach 1:

The invention segments the dosage form into two independent layers, each optimized for its specific drug's release characteristics. This segmentation allows each layer to be manufactured and controlled independently, achieving coordinated release profiles for APAP and tramadol while maintaining manufacturing feasibility through established tabletting techniques.

Inventive Principle:
Principle #1Segmentation

4Adaptability or versatility

If different release rates are used for APAP and tramadol, then absorption differences are accommodated, but plasma concentration fluctuations become unpredictable

Engineering Contradiction:
Improveabsorption accommodationVSAvoidplasma concentration predictability
Core Design Contradiction:
Adaptability or versatilityVSReliability

Solution Approach 1:

The invention assigns different release qualities to different layers: the immediate release layer rapidly releases APAP to match its fast absorption and short half-life, while the extended release layer slowly releases tramadol to match its slower absorption and longer half-life. This localized optimization of release characteristics for each drug ensures predictable plasma concentration profiles despite their different pharmacokinetic properties.

Inventive Principle:
Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach results in a sustained release of both drugs with a near-zero-order release kinetics, reducing the release rate gap and providing a consistent therapeutic effect with less frequent dosing, thus overcoming the limitations of previous formulations.

Implementation Method 1

the drug/polymer ionic interaction between tramadol and an anionic polymer provides a slow release of tramadol

Methodology Applied
Scientific EffectIonic interaction: Ion Repulsion/Attraction

Implementation Method 2

the composition exhibits coordinated sustained release upon dissolution as in oral administration in a patient

Methodology Applied
Scientific EffectDissolution: Solvation

Data Source

PatentEP2362768B1Extended release oral acetaminophen/tramadol dosage form
Publication Date: 2016.04.20 ALZA CORP
  • EP2362768B1 patent drawingFigure 1A~1C
  • EP2362768B1 patent drawingFigure 2~3
  • EP2362768B1 patent drawingFigure 4~5

AI summary

An extended release oral administered dosage form of acetaminophen and tramadol. The dosage form includes a composition of acetaminophen together with a tramadol complex formed with an anionic polymer. The tramadol complex provides sustained release of tramadol for a synchronized (coordinated) release profile of acetaminophen and tramadol.